Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PRV-6527 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| PRV-6527 | DRUG | Treatment |
| Placebo | DRUG | Comparator |
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Sanofi SA Sponsored ADR | SNY | 6 | PHASE3 | Duvakitug |
| Eli Lilly and Company | LLY | 8 | PHASE3 | Mirikizumab |
| AbbVie, Inc. | ABBV | 14 | PHASE3 | Risankizumab, Risankizumab On-Body Injector |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 16 | PHASE3 | Vedolizumab |
| Johnson & Johnson | JNJ | 13 | PHASE3 | Ustekinumab |
| Merck & Co., Inc. | MRK | 2 | PHASE3 | Tulisokibart |
| AstraZeneca PLC | AZN | 2 | PHASE2 | AZD7798 |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-0974 |
| Spyre Therapeutics, Inc | SYRE | 1 | PHASE2 | SPY001, SPY002, SPY003 |
| Abivax SA Sponsored ADR | ABVX | 1 | PHASE2 | Obefazimod |
| Palisade Bio, Inc. | PALI | 1 | PHASE1 | PALI-2108 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
| Amgen Inc. | AMGN | 1 | N/A | Undisclosed |
| TScan Therapeutics, Inc. | TCRX | 1 | - | Undisclosed |
PRV-6527 is an investigational small molecule being developed for the treatment of Crohn's disease, a type of inflammatory bowel disease. It is intended for patients with moderately to severely active Crohn's disease. The drug is currently in clinical development and has not been approved by regulatory authorities.
PRV-6527 is being developed by Sanofi, a multinational pharmaceutical company. Sanofi's stock is traded under the ticker symbol SNY. The company is conducting clinical trials to evaluate the safety and efficacy of PRV-6527 in patients with Crohn's disease.
PRV-6527 is in Phase 2 clinical development. Specifically, it has completed a Phase 2a study in subjects with moderately to severely active Crohn's disease. The drug is still investigational and has not received FDA approval. Its safety and efficacy have not been fully established.
PRV-6527 has been studied in one clinical trial, identified as NCT03854305. This was a Phase 2a study in subjects with moderately to severely active Crohn's disease. The trial has been completed and enrolled 93 participants. The study was uncontrolled, meaning there was no control group.
PRV-6527 is not FDA approved. It is an investigational drug currently in clinical development for Crohn's disease. The completed Phase 2a trial (NCT03854305) evaluated the drug in 93 patients, but further studies are needed to establish its safety and efficacy before any regulatory approval could be considered.